<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01127581</url>
  </required_header>
  <id_info>
    <org_study_id>Miso-Obs-303</org_study_id>
    <nct_id>NCT01127581</nct_id>
  </id_info>
  <brief_title>Efficacy &amp; Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery</brief_title>
  <acronym>EXPEDITE</acronym>
  <official_title>Phase III, Double-blind, Randomized, Multicenter Study of Exogenous Prostaglandin Comparing the Efficacy &amp; Safety of the MVI 200 mcg Versus the Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery in Pregnant Women at Term</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200
      microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone
      Vaginal Insert (DVI) 10 milligram (mg) in pregnant women requiring cervical ripening and
      induction of labor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Vaginal Delivery During the First Hospital Admission</measure>
    <time_frame>Interval from study drug administration to vaginal delivery (average 24 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Cesarean Delivery During the First Hospital Admission</measure>
    <time_frame>Interval from study drug administration to cesarean delivery (average 24 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Any Delivery (Vaginal or Cesarean) During the First Hospital Admission</measure>
    <time_frame>Interval from study drug administration to neonate delivery (average 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Active Labor During the First Hospital Admission</measure>
    <time_frame>Interval from study drug administration to active labor (average 12 hours)</time_frame>
    <description>Active labor was defined as progressive cervical dilatation to 4 cm with any frequency of contractions OR rhythmic, firm, adequate quality uterine contractions causing progressive cervical change occurring at a frequency of 3 or more in 10 minutes and lasting 45 seconds or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pre-delivery Oxytocin During the First Hospital Admission</measure>
    <time_frame>At least 30 minutes after study drug removal</time_frame>
    <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Vaginal Delivery Within 12 Hours</measure>
    <time_frame>Interval from study drug administration to vaginal delivery within 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Any Delivery Within 24 Hours</measure>
    <time_frame>Interval from study drug administration to delivery of neonate within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Any Delivery Within 12 Hours</measure>
    <time_frame>Interval from study drug administration to delivery of neonate within 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Vaginal Delivery Within 24 Hours</measure>
    <time_frame>Interval from study drug administration to vaginal delivery within 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Vaginal Delivery</measure>
    <time_frame>Interval from study drug administration to vaginal delivery (average 24 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>From study drug administration to hospital discharge (approximately 48-72 hours)</time_frame>
    <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1358</enrollment>
  <condition>Reducing Time to Vaginal Delivery</condition>
  <condition>Cervical Ripening</condition>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>MVI 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MVI 200 mcg vaginal insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dinoprostone Vaginal Insert (DVI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg Dinoprostone vaginal insert</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVI 200</intervention_name>
    <description>Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
    <arm_group_label>MVI 200</arm_group_label>
    <other_name>Misopess(TM)</other_name>
    <other_name>Misodel (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone Vaginal Insert (DVI)</intervention_name>
    <description>Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
    <arm_group_label>Dinoprostone Vaginal Insert (DVI)</arm_group_label>
    <other_name>Cervidil (R)</other_name>
    <other_name>Propess (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent;

          -  Pregnant women at ≥ 36 weeks 0 days inclusive gestation;

          -  Women aged 18 years or older;

          -  Candidate for pharmacological induction of labor;

          -  Single, live vertex fetus;

          -  Baseline modified Bishop score ≤ 4;

          -  Parity ≤ 3 (parity is defined as one or more births live or dead after 24 weeks
             gestation);

          -  Body Mass Index (BMI) ≤ 50 at the time of entry to the study.

        Exclusion Criteria:

          -  Women in active labor;

          -  Presence of uterine or cervical scar or uterine abnormality e.g., bicornate uterus.
             Biopsies, including cone biopsy of the cervix, are permitted;

          -  Administration of oxytocin or any cervical ripening or labor inducing agents
             (including mechanical methods) or a tocolytic drug within 7 days prior to enrollment.
             Magnesium sulfate is permitted if prescribed as treatment for pre-eclampsia or
             gestational hypertension;

          -  Severe pre-eclampsia marked by Hemolytic anemia, Elevated Liver enzymes, Low Platelet
             count (HELLP) syndrome, other end-organ affliction or Central Nervous System (CNS)
             findings other than mild headache;

          -  Fetal malpresentation;

          -  Diagnosed congenital anomalies, not including polydactyly;

          -  Any evidence of fetal compromise at baseline (e.g., non-reassuring fetal heart rate
             pattern or meconium staining);

          -  Amnioinfusion or other treatment of non-reassuring fetal status at any time prior to
             the induction attempt;

          -  Ruptured membranes ≥ 48 hours prior to the start of treatment;

          -  Suspected chorioamnionitis;

          -  Fever (oral or aural temperature &gt; 37.5°C);

          -  Any condition in which vaginal delivery is contraindicated e.g., placenta previa or
             any unexplained genital bleeding at any time after 24 weeks during this pregnancy;

          -  Known or suspected allergy to misoprostol, dinoprostone, other prostaglandins or any
             of the excipients;

          -  Any condition urgently requiring delivery;

          -  Unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maricopa Medical Center - District Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Perinatal Associates (Scottsdale Healthcare Shea)</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watching Over Mothers and Babies Foundation</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller's Childrens Hospital</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Clinic of Northern Colorado</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System (DE Center for MFM)</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of FL College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peters University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico/New Mexico Health Science Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University, Brody School of Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Gynecologic Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Group/Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT College of Medicine Chattanooga, Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High Risk Obstetrical Consultants, PLLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Memphis Associates</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salt Lake Women's Center, PC</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Research Foundation</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2010</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>January 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2014</results_first_posted>
  <disposition_first_submitted>April 12, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 12, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 19, 2013</disposition_first_posted>
  <last_update_submitted>April 15, 2014</last_update_submitted>
  <last_update_submitted_qc>April 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Misoprostol vaginal insert</keyword>
  <keyword>Dinoprostone vaginal insert</keyword>
  <keyword>Cervidil</keyword>
  <keyword>Cervical ripening</keyword>
  <keyword>Induction of labor</keyword>
  <keyword>Rate of cesarean section</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pregnant women who required to be induced were recruited at 35 sites in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="P2">
          <title>Dinoprostone Vaginal Insert (DVI)</title>
          <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="678"/>
                <participants group_id="P2" count="680"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="678"/>
                <participants group_id="P2" count="680"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="B2">
          <title>Dinoprostone Vaginal Insert (DVI)</title>
          <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="678"/>
            <count group_id="B2" value="680"/>
            <count group_id="B3" value="1358"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                    <measurement group_id="B2" value="680"/>
                    <measurement group_id="B3" value="1358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.99"/>
                    <measurement group_id="B2" value="25.9" spread="5.95"/>
                    <measurement group_id="B3" value="26.0" spread="5.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                    <measurement group_id="B2" value="680"/>
                    <measurement group_id="B3" value="1358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                    <measurement group_id="B2" value="680"/>
                    <measurement group_id="B3" value="1358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Vaginal Delivery During the First Hospital Admission</title>
        <time_frame>Interval from study drug administration to vaginal delivery (average 24 hours)</time_frame>
        <population>Subjects who underwent a cesarean delivery during the first hospitalization were censored using the longest time interval from study drug administration to cesarean delivery, independent of treatment assignment. Subjects who were discharged prior to delivery or withdrew consent prior to delivery were also censored.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Vaginal Delivery During the First Hospital Admission</title>
          <population>Subjects who underwent a cesarean delivery during the first hospitalization were censored using the longest time interval from study drug administration to cesarean delivery, independent of treatment assignment. Subjects who were discharged prior to delivery or withdrew consent prior to delivery were also censored.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1292.00" lower_limit="1200.00" upper_limit="1402.00"/>
                    <measurement group_id="O2" value="1968.50" lower_limit="1812.00" upper_limit="2093.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subjects who underwent a cesarean delivery during the first hospitalization were censored using the longest time interval from study drug administration to cesarean delivery during the first hospitalization, independent of treatment group. Subjects who, in their first hospitalization, were discharged prior to delivery or withdrew consent prior to delivery were censored using the longest time interval from study drug administration to labor and delivery discharge, independent of treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-677</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Sample size 675 per group provides 90% power to see an improvement of ≥320 minutes (20% improvement from DVI) in time to vaginal delivery between MVI 200 &amp; DVI assuming a median time of 1600 minutes for DVI &amp; 34% dropout rate based on 5% 2‑sided test</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Cesarean Delivery During the First Hospital Admission</title>
        <time_frame>Interval from study drug administration to cesarean delivery (average 24 hours)</time_frame>
        <population>Analysis was based on a between-treatment-group difference in the safety population. Subjects discharged prior to delivery, withdrew early without having a cesarean delivery or were lost-to-follow up were classified as not having the event.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cesarean Delivery During the First Hospital Admission</title>
          <population>Analysis was based on a between-treatment-group difference in the safety population. Subjects discharged prior to delivery, withdrew early without having a cesarean delivery or were lost-to-follow up were classified as not having the event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.96" lower_limit="22.70" upper_limit="29.43"/>
                    <measurement group_id="O2" value="27.06" lower_limit="23.75" upper_limit="30.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of the cesarean delivery rates during the first hospitalization was based on a between-treatment-group difference. If the upper limit of the asymptotic two-sided 95% confidence interval of the difference in event rates (MVI minus DVI) was less than the calculated non-inferiority margin (10% relative to the DVI rate, i.e., 0.1 times DVI rate), then MVI 200 would be considered non-inferior to DVI.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A sample size of 675 subjects per group will provide a sufficient number of subjects to assess non-inferiority of MVI 200 with respect to rate of cesarean delivery, based on an alpha level of 5% and 80% power for a two-sided approach using a 10% non-inferiority limit (relative to the DVI rate), assuming a 30% rate of cesarean delivery in the DVI group compared to a 26% rate in the MVI 200 group.</non_inferiority_desc>
            <param_type>Difference in Populations</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.79</ci_lower_limit>
            <ci_upper_limit>3.59</ci_upper_limit>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Any Delivery (Vaginal or Cesarean) During the First Hospital Admission</title>
        <time_frame>Interval from study drug administration to neonate delivery (average 24 hours)</time_frame>
        <population>Subjects who did not deliver during the first hospitalization were censored at the time of labour and delivery discharge.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Any Delivery (Vaginal or Cesarean) During the First Hospital Admission</title>
          <population>Subjects who did not deliver during the first hospitalization were censored at the time of labour and delivery discharge.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1096.50" lower_limit="1031.00" upper_limit="1170.00"/>
                    <measurement group_id="O2" value="1639.50" lower_limit="1573.00" upper_limit="1731.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subjects who did not deliver during the first hospitalization were censored using the longest time interval from study drug administration to labor and delivery discharge without delivery, independent of treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-543</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Active Labor During the First Hospital Admission</title>
        <description>Active labor was defined as progressive cervical dilatation to 4 cm with any frequency of contractions OR rhythmic, firm, adequate quality uterine contractions causing progressive cervical change occurring at a frequency of 3 or more in 10 minutes and lasting 45 seconds or more.</description>
        <time_frame>Interval from study drug administration to active labor (average 12 hours)</time_frame>
        <population>Intention-to-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Active Labor During the First Hospital Admission</title>
          <description>Active labor was defined as progressive cervical dilatation to 4 cm with any frequency of contractions OR rhythmic, firm, adequate quality uterine contractions causing progressive cervical change occurring at a frequency of 3 or more in 10 minutes and lasting 45 seconds or more.</description>
          <population>Intention-to-Treat (ITT) population</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726.50" lower_limit="719.00" upper_limit="773.00"/>
                    <measurement group_id="O2" value="1116.50" lower_limit="1083.00" upper_limit="1352.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Subjects who never went into active labor during the first hospitalization were censored using the longest time interval from study drug administration to delivery during the first hospitalization, independent of treatment group. Subjects who, in their first hospitalization, were discharged prior to delivery or withdrew consent prior to delivery were censored using the longest time interval from study drug administration to labor and delivery discharge, independent of treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-390</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Pre-delivery Oxytocin During the First Hospital Admission</title>
        <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal.</description>
        <time_frame>At least 30 minutes after study drug removal</time_frame>
        <population>Analysis population includes subjects who delivered during the first hospitalization.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Pre-delivery Oxytocin During the First Hospital Admission</title>
          <description>Percentage of participants in receipt of Oxytocin for induction after study drug removal.</description>
          <population>Analysis population includes subjects who delivered during the first hospitalization.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="674"/>
                <count group_id="O2" value="671"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1" lower_limit="44.24" upper_limit="51.92"/>
                    <measurement group_id="O2" value="74.1" lower_limit="70.58" upper_limit="77.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>-26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Vaginal Delivery Within 12 Hours</title>
        <time_frame>Interval from study drug administration to vaginal delivery within 12 hours</time_frame>
        <population>Intention-to-Treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Vaginal Delivery Within 12 Hours</title>
          <population>Intention-to-Treat (ITT) population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.76" lower_limit="16.83" upper_limit="22.96"/>
                    <measurement group_id="O2" value="8.38" lower_limit="6.41" upper_limit="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>9.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Any Delivery Within 24 Hours</title>
        <time_frame>Interval from study drug administration to delivery of neonate within 24 hours</time_frame>
        <population>Intention-to-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Delivery Within 24 Hours</title>
          <population>Intention-to-Treat (ITT) Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.70" lower_limit="64.03" upper_limit="71.21"/>
                    <measurement group_id="O2" value="40.74" lower_limit="37.02" upper_limit="44.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>26.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Any Delivery Within 12 Hours</title>
        <time_frame>Interval from study drug administration to delivery of neonate within 12 hours</time_frame>
        <population>Intention-to-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Delivery Within 12 Hours</title>
          <population>Intention-to-Treat (ITT) Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.16" lower_limit="20.03" upper_limit="26.52"/>
                    <measurement group_id="O2" value="9.26" lower_limit="7.19" upper_limit="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>13.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Vaginal Delivery Within 24 Hours</title>
        <time_frame>Interval from study drug administration to vaginal delivery within 24 hours</time_frame>
        <population>Intention-to-Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Vaginal Delivery Within 24 Hours</title>
          <population>Intention-to-Treat (ITT) Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.57" lower_limit="50.74" upper_limit="58.37"/>
                    <measurement group_id="O2" value="33.97" lower_limit="30.41" upper_limit="37.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>29.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Vaginal Delivery</title>
        <time_frame>Interval from study drug administration to vaginal delivery (average 24 hours)</time_frame>
        <population>The Intention-to-Treat (ITT) population was used for all secondary efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Vaginal Delivery</title>
          <population>The Intention-to-Treat (ITT) population was used for all secondary efficacy analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.30" lower_limit="69.80" upper_limit="76.60"/>
                    <measurement group_id="O2" value="71.62" lower_limit="68.07" upper_limit="74.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Proportions</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>MVI 200 - DVI</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Adverse Events</title>
        <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug.</description>
        <time_frame>From study drug administration to hospital discharge (approximately 48-72 hours)</time_frame>
        <population>The percentage of subjects with adverse events are presented for the Intrapartum (before delivery), postpartum (maternal) and neonatal periods.</population>
        <group_list>
          <group group_id="O1">
            <title>MVI 200</title>
            <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
          <group group_id="O2">
            <title>Dinoprostone Vaginal Insert (DVI)</title>
            <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adverse Events</title>
          <description>All adverse events were rated by the Investigator as mild, moderate or severe and classified as having no relationship, possible relationship or a probable relationship to the study drug.</description>
          <population>The percentage of subjects with adverse events are presented for the Intrapartum (before delivery), postpartum (maternal) and neonatal periods.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="680"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with an Intrapartum Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5"/>
                    <measurement group_id="O2" value="54.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Maternal Postpartum Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with Neonatal Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were followed until resolution or at least 30 days after discontinuation of the study drug, whichever occurred first.</time_frame>
      <desc>All adverse events occurring to the maternal-fetal unit (pre-delivery/ intrapartum), the mother (postpartum) or the neonate were recorded. Adverse events that resulted in a cesarean delivery were reported as serious adverse events as they were medically significant events that routinely prolonged the duration of hospitalization.</desc>
      <group_list>
        <group group_id="E1">
          <title>MVI 200</title>
          <description>MVI 200 mcg vaginal insert
MVI 200: Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
        <group group_id="E2">
          <title>Dinoprostone Vaginal Insert (DVI)</title>
          <description>10 mg Dinoprostone vaginal insert
Dinoprostone vaginal insert: Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Polycythaemia *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenogenital syndrome *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Anal atresia *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Ankyloglossia congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Anomalous pulmonary venous connection *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Atrial septal defect *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="678"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Cataract congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Congenital choroid plexus cyst *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Congenital hydronephrosis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Congenital nose malformation *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Congenital pyelocaliectasis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Cryptorchism *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hydrocele *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hypospadias *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="678"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Patent ductus arteriosus *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="678"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Penile torsion *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Phimosis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Polydactyly *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Pulmonary artery stenosis congenital *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Supernumerary nipple *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Syndactyly *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Talipes *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>VACTERL syndrome *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Ventricular septal defect *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Salivary gland enlargement *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endometritis #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Pneumonia *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Pneumonia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Postpartum sepsis #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Septic shock *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skull fracture *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output decreased *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding disorder neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint crepitation *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Muscular weakness #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysaesthesia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Encephalopathy neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Paraesthesia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal labour affecting foetus +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Erb's palsy *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Foetal acidosis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Foetal heart rate disorder +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="678"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Neonatal disorder *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="678"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Puerperal pyrexia #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Uterine contractions abnormal +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Uterine rupture +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Weight decrease neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Chordee *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Testicular torsion *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Vulval haematoma #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal aspiration *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory depression *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Pneumothorax *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hypertension #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="520" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="533" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abnormal labour affecting foetus +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="62" subjects_affected="59" subjects_at_risk="678"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Arrested labour +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="96" subjects_affected="96" subjects_at_risk="678"/>
                <counts group_id="E2" events="129" subjects_affected="128" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Caput succedaneum *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="678"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="678"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Foetal heart rate disorder +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="138" subjects_affected="124" subjects_at_risk="678"/>
                <counts group_id="E2" events="160" subjects_affected="138" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="678"/>
                <counts group_id="E2" events="78" subjects_affected="78" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Meconium in amniotic fluid +</sub_title>
                <description>+ Intrapartum Event</description>
                <counts group_id="E1" events="120" subjects_affected="120" subjects_at_risk="678"/>
                <counts group_id="E2" events="92" subjects_affected="92" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage #</sub_title>
                <description># Postpartum Event</description>
                <counts group_id="E1" events="41" subjects_affected="40" subjects_at_risk="678"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="680"/>
              </event>
              <event>
                <sub_title>Umbilical cord around neck *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="184" subjects_affected="184" subjects_at_risk="678"/>
                <counts group_id="E2" events="194" subjects_affected="194" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Neonatal respiratory depression *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="678"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Infection prophylaxis *</sub_title>
                <description>* Neonatal Event</description>
                <counts group_id="E1" events="46" subjects_affected="46" subjects_at_risk="678"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="680"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any abstract,presentation or manuscript proposed for publication must be submitted to the Sponsor for review at least 30 days prior to submission for any meeting or journal.If deemed necessary by the Sponsor for protection of proprietary information prior to patent filing,the Investigator agrees to a further delay of 60 days before any presentation or publication is submitted.Publications must be in a form that does not reveal technical information that is considered confidential or proprietary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Development Support</name_or_title>
      <organization>Ferring Pharmaceuticals</organization>
      <email>DK0-Disclosure@ferring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

